A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib
Crossref DOI link: https://doi.org/10.1186/s40661-016-0026-5
Published Online: 2016-05-05
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Takekuma, Munetaka
Wong, Kwong K.
Coleman, Robert L.
